Neurizon Therapeutics Ltd (ASX: NUZ) Share Price and News

Dr Thurn brings experience in drug discovery, development, regulation and commercialization, acquired through leadership roles in research organizations and industry, including early-stage, fast-growing, private and publicly listed biotechnology companies. His previous responsibilities have included leading a variety of US Food and Drug Administration Investigational New Drug applications across a range of therapeutic areas and the evaluation of drugs and vaccines for registration in Australia as a part of the Drug Safety Evaluation Branch (DSEB) of the Therapeutics Goods Administration (TGA). Michael has also been responsible for the execution of Phase 1 and 2 clinical trials and business development activities across animal and human health products. During this time, Dr Thurn has gained Australian and US capital markets exposure and has accessed funding through private and public channels, partnerships, and non-dilutive means.

Dr Katie MacFarlane has over 30 years of experience in the development and commercialization of pharmaceutical products and devices. She is the Founder and President of SmartPharma, a commercial and strategic consulting firm that specializes in market and product assessments, market sizing and forecasting, pre-launch preparation and launch and marketing of pharmaceutical products for biopharmaceutical companies. Katie also currently is the Head of Commercial for Arkayli Biopharma, a startup developing a treatment for a rare pediatric disease. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President of Marketing, Sales and New Product Planning at Warner Chilcott, and Senior Director of Marketing at Parke-Davis (now Pfizer). She previously served on the Board of Directors for RespireRx and a nonprofit, INMED Partnerships for Children

Mr Duchini brings over a decade of board-level experience with expertise spanning professional services, life sciences, biotechnology, banking, fnance, and the not-for-profit sector. His background includes roles such as Chair, Executive and Non-Executive Board Director, Risk & Audit Committee Chair, and Chief Strategy Officer. Currently, Mr Duchini serves as a Non-Executive Director and Chair of the Audit Committee at Enlitic Inc., a US company focused on leveraging artificial intelligence to enhance workflow and patient outcomes in radiology. Additionally, he holds the position of Chair at Lymphoma Australia, a not-for-profit organization supporting lymphoma patients and their caregivers in Australia. Mr Duchini's executive experience includes 23 years at Deloitte Australia where he held multiple senior positions as an equity partner. He advised Australian and international groups to manage their investments in R&D nationally and internationally, developed and executed the national tax strategy, and led senior cross-disciplinary teams serving prominent clients such as National Australia Bank, ANZ Bank, and Australia Post.

Mr Hughes has more than 20 years of experience with listed companies. He possesses corporate finance experience, having led project financing and capital raisings in the industrial sector. He has held senior managerial, tax and finance roles with multinational companies including Lend Lease, Fortescue Metals and Rio Tinto.

-

-

-